Inscription Capital’s NovoCure NVCR Stock Holding History

Inscription Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,689	Closed	-$324K	–	840
2026 Q1	$324K	Sell	29,689 -10,329	-26%	-$129K	0.03%	465
2025 Q4	$517K	Buy	40,018 +4,646	+13%	+$59.6K	0.05%	351
2025 Q3	$457K	Buy	35,372 +15,681	+80%	+$210K	0.05%	378
2025 Q2	$351K	Buy	+19,691	New	+$343K	0.05%	313

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Inscription Capital's NVCR Position: Q2 2026 in Review

Inscription Capital sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 29,689 shares — an estimated $324K sold.

Inscription Capital first reported a position in NVCR in Q2 2025 and held it in 4 quarters. The position peaked at $517K in Q4 2025. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Inscription Capital reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Inscription Capital sold 29,689 NovoCure shares in Q2 2026, an estimated $324K.
Inscription Capital first reported a position in NovoCure in Q2 2025 and held it in 4 quarters.
Inscription Capital's NovoCure position peaked at $517K in Q4 2025.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.